Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Diaceutics PLC (DXRX.L)
Belfast, GB
Diaceutics PLC, established in 2005 and headquartered in Belfast, UK, is a company dedicated to accelerating the commercialization of diagnostic solutions. It offers global pharmaceutical companies comprehensive data, advanced analytics, and implementation support. Central to its operations is the DXRX platform. This platform features DXRX data solutions, providing access to extensive diagnostic testing data pipelines from a broad network of laboratories, including real-time DXRX signal alerts, lab and physician mapping, and a testing dashboard. The DXRX platform also hosts a marketplace where laboratories, pharmaceutical firms, and diagnostic companies can connect to collaborate on precision medicine diagnostics. Diaceutics further provides DXRX Patient Journey, a tool for pharmaceutical clients to conduct detailed longitudinal analyses of individual patient biomarker testing paths, helping identify opportunities for earlier intervention and treatment. DXRX Lab Benchmarking allows laboratories to sharpen their competitive edge by comparing their key criteria against industry counterparts, encompassing metrics such as disease focus, testing methodologies, market share, turnaround times, and their standing as leaders in specific diagnostic fields. The DXRX Test Reimbursement service assists pharma clients in funding novel companion diagnostics, thereby shortening the time required for their widespread adoption. Furthermore, DXRX Test Signal delivers immediate notifications of testing events, empowering pharmaceutical clients to swiftly identify therapeutically actionable patients. Beyond the platform, Diaceutics furnishes services for diagnostic landscape analysis, strategic planning, implementation, and ongoing tracking, alongside expert consulting tailored to precision medicine diagnostics. Its extensive service portfolio also covers test standardization, quality evaluations, optimization of test reports, technical laboratory support, assistance with test access and reimbursement, laboratory training, and various educational resources.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.70% | -15.88% | -13.60% | -4.98% | -5.30% | +11.72% | +4.00% | +76.54% | +10.85% | +49.74% | +49.74% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+19.5% ★ Q4'25: +73.3% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%+105.5% ★ Q4'25: +1,051.6% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+2.0% Q4'25: +2.8% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-0.6% Q4'25: +13.1% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%-0.4% Q4'25: +27.2% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%+0.8% Q4'25: +0.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.21× ★ Q4'25: 0.05× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 4 Rev. Ana. 2 EPS Ana. |
Dec 2028 4 Rev. Ana. 1 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
13.44M
est: 13.40M (+0.3%)
|
12.70M
est: 12.60M (+0.8%)
|
13.94M
est: 13.90M (+0.3%)
|
19.50M
est: 20.00M (-2.5%)
|
23.70M
est: 26.10M (-9.2%)
|
32.16M
est: 32.20M (-0.1%)
|
38.44M
est: 38.44M (+0.0%)
|
46.32M
45.82M – 46.83M
+20.5% YoY
|
55.90M
54.21M – 58.93M
+20.7% YoY
|
66.39M
65.31M – 67.46M
+18.8% YoY
|
76.30M
74.66M – 78.95M
+14.9% YoY
|
| EBITDA |
847.6K
est: 1.48M (-42.8%)
|
178.0K
est: 1.40M (-87.2%)
|
2.35M
est: 1.54M (+52.6%)
|
3.61M
est: 997.0K (+261.9%)
|
2.36M
est: 3.57M (-34.0%)
|
2.77M
est: 4.41M (-37.1%)
|
5.60M
est: 5.27M (+6.4%)
|
6.35M
6.28M – 6.41M
+20.5% YoY
|
7.66M
7.43M – 8.07M
+20.7% YoY
|
9.09M
8.95M – 9.24M
+18.8% YoY
|
10.45M
10.23M – 10.81M
+14.9% YoY
|
| EBIT |
562.7K
est: -372.5K (+251.1%)
|
-631.0K
est: -350.7K (-79.9%)
|
550.0K
est: -386.9K (+242.2%)
|
600.0K
est: 1.37M (-56.2%)
|
-2.41M
est: -494.9K (-387.8%)
|
-1.85M
est: -610.6K (-203.6%)
|
-212.0K
est: -728.9K (+70.9%)
|
-878.5K
-888.0K – -869.0K
-20.5% YoY
|
-1.06M
-1.12M – -1.03M
-20.7% YoY
|
-1.26M
-1.28M – -1.24M
-18.8% YoY
|
-1.45M
-1.50M – -1.42M
-14.9% YoY
|
| Net Income |
398.0K
est: 1.94M (-79.5%)
|
263.0K
est: -2.20M (+112.0%)
|
561.0K
est: 582.0K (-3.6%)
|
724.0K
est: 6.0K (+11,966.7%)
|
-1.75M
est: -2.85M (+38.6%)
|
-1.70M
est: -586.6K (-190.3%)
|
97.0K
est: 97.0K (+0.0%)
|
510.8K
395.3K – 626.2K
+426.6% YoY
|
2.66M
1.93M – 3.39M
+420.5% YoY
|
7.20M
7.08M – 7.61M
+170.8% YoY
|
10.88M
10.57M – 11.37M
+51.1% YoY
|
| SGA |
8.19M
est: 11.09M (-26.2%)
|
9.94M
est: 10.44M (-4.8%)
|
10.25M
est: 12.27M (-16.4%)
|
13.71M
est: 15.51M (-11.7%)
|
22.78M
est: 21.03M (+8.4%)
|
30.74M
est: 25.94M (+18.5%)
|
25.88M
est: 30.97M (-16.4%)
|
37.33M
36.92M – 37.73M
+20.5% YoY
|
45.04M
43.68M – 47.48M
+20.7% YoY
|
53.49M
52.62M – 54.36M
+18.8% YoY
|
61.48M
60.16M – 63.61M
+14.9% YoY
|
| EPS |
0.01
est: 0.02 (-73.0%)
|
0.00
est: -0.03 (+113.1%)
|
0.01
est: 0.01 (-42.2%)
|
0.01
est: 0.00 (+82.1%)
|
-0.02
est: -0.03 (+38.6%)
|
-0.02
est: -0.01 (-195.7%)
|
0.00
est: 0.00 (+9.1%)
|
0.01
0.00 – 0.01
+445.5% YoY
|
0.03
0.02 – 0.04
+450.0% YoY
|
0.09
0.08 – 0.09
+159.3% YoY
|
0.13
0.12 – 0.13
+49.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-27 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-21 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ryan Keeling | Chief Executive Officer & Director | 541.5K | male |
| Nicholas Stewart Roberts | Chief Financial Officer, Secretary & Director | 387.3K | male |
| Peter Keeling | Founder & Executive Chairman | 339.7K | male |
| Jordan Clark | Chief Data Officer? & Executive Director | 251.0K | male |
| Marianna Sciortino | Vice President of Sales | — | — |
| Amie McNiece | Vice President of Marketing | — | — |
| Sandra Blake | Chief People Officer | — | female |
| Ken Ruppel | Vice President of Scientific & Medical Services | — | — |
| Kerri Donaldson | Vice President of Operations | — | — |
| Lauren DeWitt | Executive Vice President of Legal, General Counsel & Group Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DXRX.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
